Janssen presents one-shot COVID-19 vaccine data
J&J subsidiary Janssen Pharma has presented updated Phase I/II antibody levels supporting a single shot administration for its COVID-19 vaccine.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1123 entries already.
Entries by Thomas Gabrielczyk
German researchers find reason for remdesivir’s inefficiency
/in News/by Thomas GabrielczykGerman Researchers have unraveled how remdesivir interferes with the viral RNA polymerase and why it does not block SARS-CoV-2 completely.
LSP reports first closing of dementia fund
/in News/by Thomas GabrielczykEuropean life sciences investors LSP has closed a new fund to fight dementia at 50m.
Valneva in talks with EU about 60 million vaccine doses
/in News/by Thomas GabrielczykFrench Valneva SE announced it is in advanced discussions with the European Commission (EC) for the supply of up to 60 million doses of its COVID-19 vaccine, VLA2001.
Immunocore bags US$75m in Series C round
/in News/by Thomas GabrielczykImmuno-oncology specialist Immunocore plc announced the completion of a $75m Series C private financing round.
EU approves second COVID-19 vaccine
/in News/by Thomas GabrielczykFollowing a recommendation by the European Medicines Agency (EMA), the European Commission has approved a second vaccine against the novel coronavirus SARS-CoV-2.
Angelini Pharma to take over Arvelle Therapeutics
/in News/by Thomas GabrielczykItalian Angelini Pharma and Swiss CNS disease specialist Arvelle Therapeutics have entered into a definitive merger agreement.
COVID-19 test gives results within minutes
/in News/by Thomas GabrielczykUniversity of Birmingham researchers have invented a COVID-19 RNA test that reduces testing time from 30 minutes to under five, and delivers accurate results.
EMA greenlights BioNtech’s COVID-19 vaccine
/in News/by Thomas GabrielczykFollowing a rapid FDA approval, the European drug authority EMA has recommended to conditionally approve BioNTechs mRNA vaccine BNT162b2 in the EU.
European Circular Bioeconomy Fund growing
/in News/by Thomas GabrielczykOnly two and a half months after its launch, the EU bioecocomy venture capital fund ECBF has doubled the volume of its first closing.